Patient Data as a Strategic Asset: The Pharma Opportunity You're Underutilizing

Patient access to their medical records seems like the proverbial no-brainer, but it is only recently that the 21^st Century Cures Act formally established patients’ rights to their own data.  Innovative platforms like Health Bank One™ now make that right actionable, giving patients access to their consolidated medical records, retrieved from whatever provider the patient may have seen.  As I see it, however, this level of access is just the tip of the iceberg: the real value of patient-controlled EMR access has yet to be fully realized!

Patients (and their providers) certainly value access to consolidated medical records to support treatment decisions and other useful insights, such as:

·       Are there clinical trials I might qualify for?

·       Have my clinical measures evolved over time?

·       How do clinical outcomes of people using similar treatments compare with mine?

However, when that data access is paired with research opportunities, information about their condition, access to communities, and even direct product purchasing, it transforms the transactional patient experience into an opportunity for sustained engagement.  The Health Bank One experience, including Care Gude™ AI, is built to enable exactly that.

At the same time, nothing gets a life-sciences company more excited than the prospect of stakeholder (patients, providers, and even payers) engagement.  The most direct benefit a company can realize in gaining access to patient-consented medical records is the real-world data that can support evidence of a product’s clinical, economic, or humanistic value. But, the benefits don’t stop there. The opportunity to tap into a community of engaged patients directly supports the company mission of improving health outcomes. Health Bank One gives pharma partners a platform that works across the enterprise:

• Medical Affairs and HEOR teams can use it to generate real-world evidence

• Clinical and R&D teams can use it to identify and qualify candidates to improve the design and operational efficiency of research

• Pharmacovigilance, Market Access, Commercial teams can use it to support everything from post-approval safety surveillance to direct product purchasing and patient support programs.

  
  

This is the win-win scenario: through better access to medical records data for all stakeholders, pharma companies can improve their ability to get the right medicines to the right patients as quickly as possible.